Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer

Cancer

Volumn 117, Issue 6, 2011, Pages 1190-1196

  Caffo, Orazio ^a   Fellin, Gianni ^a   Graffer, Umberto ^a   Mussari, Salvatore ^a   Tomio, Luigi ^a   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

conservative treatment; gemcitabine; infiltrating bladder cancer; multidisciplinary management; radiochemotherapy

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CANCER CONTROL; CANCER INFILTRATION; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SURGICAL APPROACH; TREATMENT RESPONSE; URINARY TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DEOXYCYTIDINE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; SURVIVAL RATE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 79952417582     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25667     Document Type: Article

References (17)

1. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55: 815-825.
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675. (Pubitemid 32120143)
3. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21: 690-696. (Pubitemid 46621904)
4. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG,. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006; 176: 486-492. (Pubitemid 43927871)
5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859-866. (Pubitemid 37025405)
6. Shipley WU, Kaufman D, Zehr EM, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002; 60: 62-67. (Pubitemid 34722947)
7. Rodel C, Weiss C, Sauer R., Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006; 24: 5536-5544. (Pubitemid 46631334)
8. Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998; 40: 121-127.
9. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 48: 189-199.
10. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
11. Caffo O, Fellin G, Graffer U, et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003; 57: 1310-1316. (Pubitemid 37443970)
12. Kaplan E, Meier P., Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
13. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005; 47: 69-80. (Pubitemid 39643243)
14. Shewach DS, Lawrence TS., Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol. 1996; 23 (5 suppl 10): 65-71. (Pubitemid 26362198)
15. Kent E, Sandler H, Montie J, et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol. 2004; 22: 2540-2545. (Pubitemid 41103741)
16. Sangar VK, McBain CA, Lyons J, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005; 61: 420-425. (Pubitemid 40164436)
17. Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM., Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009; 74: 511-517.